One of the primary barriers to the growth of the digital health category around the world are fragmented, contradictory, or even entirely absent mechanisms for reimburseme
Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market.
Biogen has scaled back its ambitions for Denali-partnered Parkinson’s disease candidate BIIB122, abandoning a complex and likely costly phase 3 trial that isn’t due to com
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas